다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of pathology and translational medicine : JPTM, v.55 no.3, 2021년, pp.163 - 170
Lee, Kyu Sang (Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea) , Choe, Gheeyoung (Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea)
AI-Helper
Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibition has revolutionized the treatment paradigm of urothelial carcinoma (UC). Several PD-L1 assays are conducted to formulate appropriate treatment decisions for PD-1/PD-L1 target therapy in UC. However, each assay has its o...
1 Hirsch L Zitvogel L Eggermont A Marabelle A PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade Br J Cancer 2019 120 3 5 30413824
2 Kerr KM Tsao MS Nicholson AG Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015 10 985 9 26134220
3 Rijnders M van der Veldt AA Zuiverloon TC PD-L1 antibody comparison in urothelial carcinoma Eur Urol 2019 75 538 40 30497882
4 Ratcliffe MJ Sharpe A Midha A Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer Clin Cancer Res 2017 23 3585 91 28073845
5 Rimm DL Han G Taube JM A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer JAMA Oncol 2017 3 1051 8 28278348
6 Scheel AH Dietel M Heukamp LC Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas Mod Pathol 2016 29 1165 72 27389313
7 Hodgson A Slodkowska E Jungbluth A PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma Am J Surg Pathol 2018 42 1059 66 29750666
8 Zavalishina L Tsimafeyeu I Povilaitite P RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PDL1 expression in urothelial bladder cancer Virchows Arch 2018 473 719 24 30209552
9 Zajac M Scott M Ratcliffe M Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma Diagn Pathol 2019 14 99 31477145
10 Scheerens H Malong A Bassett K Current status of companion and complementary diagnostics: strategic considerations for development and launch Clin Transl Sci 2017 10 84 92 28121072
11 Rosenberg JE Hoffman-Censits J Powles T Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 2016 387 1909 20 26952546
12 Balar AV Castellano D O'Donnell PH First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Lancet Oncol 2017 18 1483 92 28967485
13 Powles T O’Donnell PH Massard C Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study JAMA Oncol 2017 3 e172411 28817753
14 Sharma P Retz M Siefker-Radtke A Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Lancet Oncol 2017 18 312 22 28131785
15 Kulangara K Zhang N Corigliano E Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer Arch Pathol Lab Med 2019 143 330 7 30028179
16 Adam J Le Stang N Rouquette I Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer Ann Oncol 2018 29 953 8 29351573
17 Torlakovic E Lim HJ Adam J “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy Mod Pathol 2020 33 4 17 31383961
18 Hirsch FR McElhinny A Stanforth D PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blue-print PD-L1 IHC assay comparison project J Thorac Oncol 2017 12 208 22 27913228
19 Buttner R Gosney JR Skov BG Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer J Clin Oncol 2017 35 3867 76 29053400
20 Schwamborn K Ammann JU Knuchel R Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays Virchows Arch 2019 475 599 608 31267201
21 Downes MR Slodkowska E Katabi N Jungbluth AA Xu B Interand intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma Histopathology 2020 76 191 200 31243779
22 Cooper WA Russell PA Cherian M Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer Clin Cancer Res 2017 23 4569 77 28420726
23 Chang S Park HK Choi YL Jang SJ Interobserver reproducibility of PD-L1 biomarker in non-small cell lung cancer: a multi-institutional study by 27 pathologists J Pathol Transl Med 2019 53 347 53 31656061
24 Li H Zhang Q Shuman L Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes Sci Rep 2020 10 1439 31996725
25 Reis H Serrette R Posada J PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies Am J Surg Pathol 2019 43 920 7 31135485
26 Mahoney KM Sun H Liao X PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells Cancer Immunol Res 2015 3 1308 15 26546452
27 Wu P Wu D Li L Chai Y Huang J PD-L1 and survival in solid tumors: a meta-analysis PLoS One 2015 10 e0131403 26114883
28 Ding X Chen Q Yang Z Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis Cancer Manag Res 2019 11 4171 84 31190987
29 Wen Y Chen Y Duan X The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis Clin Exp Med 2019 19 407 16 31407099
30 Kawahara T Ishiguro Y Ohtake S PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer BMC Urol 2018 18 97 30400941
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.